Dean Bajorin
迪恩·巴乔林
MD
Attending Physician, Genitourinary Oncology Service泌尿生殖肿瘤科主治医师
👥Biography 个人简介
Dean Bajorin is a leading bladder cancer specialist at MSKCC with decades of experience in urothelial carcinoma clinical trials. He played a pivotal role in enfortumab vedotin development and has shaped global standards for advanced bladder cancer treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Enfortumab Vedotin Development
Led pivotal EV-301 trial establishing enfortumab vedotin as a standard of care for platinum-pretreated advanced urothelial carcinoma, demonstrating significant overall survival benefit.
Bladder Cancer Clinical Trials
Conducted landmark trials defining cisplatin-based combination chemotherapy regimens that remain foundational in metastatic urothelial carcinoma management worldwide.
Representative Works 代表性著作
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
New England Journal of Medicine (2021)
EV-301 trial showing enfortumab vedotin improved overall survival versus chemotherapy in platinum-pretreated advanced urothelial carcinoma.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
New England Journal of Medicine (2017)
KEYNOTE-045 trial demonstrating pembrolizumab superiority over chemotherapy as second-line treatment for advanced urothelial carcinoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 迪恩·巴乔林 的研究动态
Follow Dean Bajorin's research updates
留下邮箱，当我们发布与 Dean Bajorin（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment